Literature DB >> 11245643

Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation.

D Zohlnhöfer1, C A Klein, T Richter, R Brandl, A Murr, T Nührenberg, A Schömig, P A Baeuerle, F J Neumann.   

Abstract

BACKGROUND: Restenosis due to neointima formation is the major limitation of stent-supported balloon angioplasty. Despite abundant animal data, molecular mechanisms of neointima formation have been investigated on only a limited basis in patients. This study sought to establish a method for profiling gene expression in human in-stent neointima and to identify differentially expressed genes that may serve as novel therapeutic targets. METHODS AND
RESULTS: We retrieved tissue specimens from patients with symptomatic in-stent restenosis using a novel helix cutter atherectomy device. cDNA samples prepared from neointima (n=10) and, as a control, from the media of normal arteries (n=14) were amplified using a novel polymerase chain reaction protocol and hybridized to cDNA arrays. Immunohistochemistry characterized the atherectomy material as neointima. cDNA arrays readily identified differentially expressed genes. Some of the differentially expressed genes complied with expected gene expression patterns of neointima, including downregulation of desmin and upregulation of thrombospondin-1, cyclooxygenase-1, and the 70-kDa heat shock protein B. Additionally, we discovered previously unknown gene expression patterns, such as downregulation of mammary-derived growth inhibitor and upregulation of FK506-binding protein 12 (FKBP12). Upregulation of FKBP12 was confirmed at the protein level in neointimal smooth muscle cells.
CONCLUSIONS: Gene expression patterns of human neointima retrieved by helix-cutter atherectomy can be reliably analyzed by cDNA array technology. This technique can identify therapeutic targets in patients, as exemplified by the findings regarding FKBP12. FKBP12 is the receptor for Rapamycin (sirolimus), which in animal models reduced neointima formation. Our study thus yields a rationale for the use of Rapamycin to prevent restenosis in patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245643     DOI: 10.1161/01.cir.103.10.1396

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  Rapamycin eluting stent: the onset of a new era in interventional cardiology.

Authors:  P W Serruys; E Regar; A J Carter
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

2.  Stent elution rate determines drug deposition and receptor-mediated effects.

Authors:  Abraham R Tzafriri; Adam Groothuis; G Sylvester Price; Elazer R Edelman
Journal:  J Control Release       Date:  2012-05-26       Impact factor: 9.776

Review 3.  Therapeutic advances in interventional neurology.

Authors:  Jawad F Kirmani; Nazli Janjua; Ammar Al Kawi; Shafiuddin Ahmed; Ismail Khatri; Ali Ebrahimi; Afshin A Divani; Adnan I Qureshi
Journal:  NeuroRx       Date:  2005-04

Review 4.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

5.  Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis.

Authors:  Santhi K Ganesh; Jungnam Joo; Kimberly Skelding; Laxmi Mehta; Gang Zheng; Kathleen O'Neill; Eric M Billings; Anna Helgadottir; Karl Andersen; Gudmundur Thorgeirsson; Thorarinn Gudnason; Nancy L Geller; Robert D Simari; David R Holmes; William W O'Neill; Elizabeth G Nabel
Journal:  BMC Med Genomics       Date:  2011-02-28       Impact factor: 3.063

6.  Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model.

Authors:  B Scheller; A Grandt; S Wnendt; G Lorenz; M Böhm; G Nickenig
Journal:  Z Kardiol       Date:  2005-07

7.  Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings.

Authors:  Abraham R Tzafriri; Fernando Garcia-Polite; Xiaojian Li; John Keating; Josep-Maria Balaguer; Brett Zani; Lynn Bailey; Peter Markham; Timothy C Kiorpes; Wenda Carlyle; Elazer R Edelman
Journal:  J Control Release       Date:  2018-02-05       Impact factor: 9.776

8.  Stainless steel ions stimulate increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: implications for in-stent restenosis.

Authors:  Manuel A Pallero; Melissa Talbert Roden; Yiu-Fai Chen; Peter G Anderson; Jack Lemons; Brigitta C Brott; Joanne E Murphy-Ullrich
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

9.  Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts.

Authors:  Yanpeng Diao; Steve Guthrie; Shen-Ling Xia; Xiaosen Ouyang; Li Zhang; Jing Xue; Pui Lee; Maria Grant; Edward Scott; Mark S Segal
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

10.  Lesion complexity determines arterial drug distribution after local drug delivery.

Authors:  Abraham R Tzafriri; Neda Vukmirovic; Vijaya B Kolachalama; Irina Astafieva; Elazer R Edelman
Journal:  J Control Release       Date:  2009-11-17       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.